Manesh Patel, MD
Internal Medicine · Durham, NCNPI 1487696365
Payments from drug & device makers
Across 320 payments — averaging $85,075 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$25.7M
- Regeneron$434K
- Medtronic$397K
- Amgen$213K
- Roche Molecular Systems, Inc.$188K
- Johnson & Johnson$154K
- plus $116K from 16 others
Across 6 payments — averaging $623.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
- Modernatx, Inc.$1K
- Novartis Pharma AG$28
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 92 | $25,720,608 |
| Regeneron | 27 | $434,398 |
| Medtronic(2 entities) | 59 | $397,095 |
| Amgen(2 entities) | 14 | $212,675 |
| Roche Molecular Systems, Inc. | 1 | $188,290 |
| Johnson & Johnson | 48 | $154,422 |
| Bayer | 21 | $38,090 |
| Esperion Therapeutics, Inc. | 9 | $16,577 |
| Idorsia Pharmaceuticals US Inc | 2 | $15,878 |
| Gilead | 1 | $10,680 |
| Novartis | 11 | $7,652 |
| Philips North America LLC | 5 | $6,579 |
| Janssen Global Services, LLC | 4 | $6,061 |
| Modernatx, Inc. | 11 | $6,000 |
| Abbott | 5 | $4,109 |
| Novo Nordisk AS | 1 | $3,000 |
| Janssen Scientific Affairs, LLC | 2 | $1,265 |
| Astrazeneca UK Limited | 2 | $205 |
| United Therapeutics Corporation | 1 | $128 |
| Novo Nordisk | 1 | $120 |
| Coloplast | 2 | $67 |
| Janssen Research & Development, LLC | 1 | $14 |
How this compares
$27,223,910 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Durham
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- April SalamaDurham$6.5M
- Hope UronisDurham$5M
- Richard RiedelDurham$2.6M
- Jamie ToddDurham$1.9M
- Nirmish ShahDurham$1.8M
- Aparna SwaminathanDurham$1.2M
- Cynthia MoylanDurham$907K
- Mehri McKellarDurham$824K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.